Quarterly Result6 Aug 2026, 12:52 pm
Suven Life Sciences Declares Un-audited Results for Q1 FY27
AI Summary
Suven Life Sciences Ltd announced its un-audited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results along with the limited review reports from the statutory auditors. The meeting to approve these results was held on August 6, 2026. The company also provided a link for patent updates.
Key Highlights
- Un-audited financial results for Q1 FY27 declared.
- Results are both standalone and consolidated.
- Statutory auditors' limited review reports are enclosed.
- Board meeting held on August 6, 2026, approved the results.
Price Impact
More from SUVEN
Clinical Trial2d ago, 11:57 am
Suven Life Sciences Completes Patient Enrollment for Alzheimer's Drug Study
Regulatory11 Aug, 12:34 pm
Suven Life Sciences: Monitoring Agency Report for Q2 2026
Quarterly Result6 Aug, 12:48 pm
Consolidated loss widens 148% YoY to ₹127.6 Cr as R&D spend surges on Phase 3 trials